来自中国南京的多重耐药淋病奈瑟菌分离株对新型DNA旋转酶抑制剂ETX0914（AZD0914）的杀伤敏感。
Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).
作者信息
Su Xiao-Hong, Wang Bao-Xi, Le Wen-Jing, Liu Yu-Rong, Wan Chuan, Li Sai, Alm Richard A, Mueller John P, Rice Peter A
机构信息
National Center for STD and Leprosy Control, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.
National Center for STD and Leprosy Control, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China
出版信息
Antimicrob Agents Chemother. 2015 Oct 19;60(1):621-3. doi: 10.1128/AAC.01211-15. Print 2016 Jan.
Abstract
We tested the activity of ETX0914 against 187 Neisseria gonorrhoeae isolates from men with urethritis in Nanjing, China, in 2013. The MIC50, MIC90, and MIC range for ETX0914 were 0.03 μg/ml, 0.06 μg/ml, and ≤0.002 to 0.125 μg/ml, respectively. All isolates were resistant to ciprofloxacin, and 36.9% (69/187) were resistant to azithromycin. Of the isolates, 46.5% were penicillinase-producing N. gonorrhoeae (PPNG), 36% were tetracycline-resistant N. gonorrhoeae (TRNG), and 13% (24 isolates) had an MIC of 0.125 μg/ml for ceftriaxone. ETX0914 may be an effective treatment option for gonorrhea.
摘要
2013年，我们在中国南京检测了ETX0914对187株来自患尿道炎男性的淋病奈瑟菌分离株的活性。ETX0914的MIC50、MIC90和MIC范围分别为0.03μg/ml、0.06μg/ml和≤0.002至0.125μg/ml。所有分离株对环丙沙星耐药，36.9%（69/187）对阿奇霉素耐药。在这些分离株中，46.5%是产青霉素酶淋病奈瑟菌（PPNG），36%是四环素耐药淋病奈瑟菌（TRNG），13%（24株）对头孢曲松的MIC为0.125μg/ml。ETX0914可能是淋病的一种有效治疗选择。
相似文献
1
Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914).
Antimicrob Agents Chemother. 2015 Oct 19;60(1):621-3. doi: 10.1128/AAC.01211-15. Print 2016 Jan.
2
Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
J Biol Chem. 2015 Aug 21;290(34):20984-20994. doi: 10.1074/jbc.M115.663534. Epub 2015 Jul 6.
3
High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.
Antimicrob Agents Chemother. 2015 Sep;59(9):5220-5. doi: 10.1128/AAC.00786-15. Epub 2015 Jun 15.
4
In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione.
Int J Antimicrob Agents. 2016 Sep;48(3):328-30. doi: 10.1016/j.ijantimicag.2016.05.018. Epub 2016 Jul 12.
5
Susceptibility Trends of Zoliflodacin against Multidrug-Resistant Clinical Isolates in Nanjing, China, 2014 to 2018.
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.00863-20.
6
High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.
Antimicrob Agents Chemother. 2014 Sep;58(9):5585-8. doi: 10.1128/AAC.03090-14. Epub 2014 Jun 30.
7
High percentages of resistance to tetracycline and penicillin and reduced susceptibility to azithromycin characterize the majority of strain types of Neisseria gonorrhoeae isolates in Cuba, 1995-1998.
Sex Transm Dis. 2003 May;30(5):443-8. doi: 10.1097/00007435-200305000-00012.
8
Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from symptomatic men attending the Nanjing sexually transmitted diseases clinic (2011-2012): genetic characteristics of isolates with reduced sensitivity to ceftriaxone.
BMC Infect Dis. 2014 Nov 27;14:622. doi: 10.1186/s12879-014-0622-0.
9
Emergence of quinolone resistance and cephalosporin MIC creep in Neisseria gonorrhoeae isolates from a cohort of young men in Kisumu, Kenya, 2002 to 2009.
Antimicrob Agents Chemother. 2011 Aug;55(8):3882-8. doi: 10.1128/AAC.00155-11. Epub 2011 May 23.
10
Efficacy of Gentamicin Alone and in Combination with Ceftriaxone, Ertapenem, and Azithromycin against Multidrug-Resistant Neisseria gonorrhoeae.
Microbiol Spectr. 2021 Oct 31;9(2):e0018121. doi: 10.1128/Spectrum.00181-21. Epub 2021 Oct 20.
引用本文的文献
1
Tetracycline-resistant global estimates-impacts on doxycycline post-exposure prophylaxis implementation and monitoring: a systematic review.
JAC Antimicrob Resist. 2025 Jul 9;7(4):dlaf120. doi: 10.1093/jacamr/dlaf120. eCollection 2025 Aug.
2
Late-stage functionalization of 5-nitrofurans derivatives and their antibacterial activities.
RSC Adv. 2023 Jan 20;13(5):3204-3209. doi: 10.1039/d2ra07676d. eCollection 2023 Jan 18.
3
Molecular Regulatory Mechanisms Drive Emergent Pathogenetic Properties of .
Microorganisms. 2022 Apr 28;10(5):922. doi: 10.3390/microorganisms10050922.
4
Susceptibility Trends of Zoliflodacin against Multidrug-Resistant Clinical Isolates in Nanjing, China, 2014 to 2018.
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.00863-20.
5
Azithromycin resistant gonococci: a literature review.
Antimicrob Resist Infect Control. 2020 Aug 18;9(1):138. doi: 10.1186/s13756-020-00805-7.
6
Global Network Analysis of Neisseria gonorrhoeae Identifies Coordination between Pathways, Processes, and Regulators Expressed during Human Infection.
mSystems. 2020 Feb 4;5(1):e00729-19. doi: 10.1128/mSystems.00729-19.
7
High susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical isolates from Thailand (2018) and South Africa (2015-2017).
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01479-19. Epub 2019 Sep 23.
8
Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin.
J Clin Microbiol. 2019 Aug 26;57(9). doi: 10.1128/JCM.00567-19. Print 2019 Sep.
9
Systematic review and survey of Neisseria gonorrhoeae ceftriaxone and azithromycin susceptibility data in the Asia Pacific, 2011 to 2016.
PLoS One. 2019 Apr 3;14(4):e0213312. doi: 10.1371/journal.pone.0213312. eCollection 2019.
10
Transcriptome Analysis of Neisseria gonorrhoeae during Natural Infection Reveals Differential Expression of Antibiotic Resistance Determinants between Men and Women.
mSphere. 2018 Jun 27;3(3). doi: 10.1128/mSphereDirect.00312-18. Print 2018 Aug 29.
本文引用的文献
1
In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.
Antimicrob Agents Chemother. 2015 Oct;59(10):6053-63. doi: 10.1128/AAC.01016-15. Epub 2015 Jul 20.
2
Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
J Biol Chem. 2015 Aug 21;290(34):20984-20994. doi: 10.1074/jbc.M115.663534. Epub 2015 Jul 6.
3
High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.
Antimicrob Agents Chemother. 2015 Sep;59(9):5220-5. doi: 10.1128/AAC.00786-15. Epub 2015 Jun 15.
4
Twenty-five-year changing pattern of gonococcal antimicrobial susceptibility in Shanghai: surveillance and its impact on treatment guidelines.
BMC Infect Dis. 2014 Dec 30;14:731. doi: 10.1186/s12879-014-0731-9.
5
Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 2015 Mar;59(3):1478-86. doi: 10.1128/AAC.04456-14. Epub 2014 Dec 22.
6
Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated from Guangzhou, China, 2000 to 2005 and 2008 to 2013.
Sex Transm Dis. 2015 Jan;42(1):27-9. doi: 10.1097/OLQ.0000000000000218.
7
Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from symptomatic men attending the Nanjing sexually transmitted diseases clinic (2011-2012): genetic characteristics of isolates with reduced sensitivity to ceftriaxone.
BMC Infect Dis. 2014 Nov 27;14:622. doi: 10.1186/s12879-014-0622-0.
8
In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.
Antimicrob Agents Chemother. 2015 Jan;59(1):467-74. doi: 10.1128/AAC.04124-14. Epub 2014 Nov 10.
9
Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014.
Euro Surveill. 2014 Jul 31;19(30):20862. doi: 10.2807/1560-7917.es2014.19.30.20862.
10
Antibiotic susceptibility of Neisseria gonorrhoeae isolates from Guangzhou, China, during 2002-2011.
Jpn J Infect Dis. 2014;67(4):288-91. doi: 10.7883/yoken.67.288.
Zotero 插件